Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 17/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 16/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3076172 | 0.78 | ADORA2B (1.00) | ADORA2AADORA2BADORA1ADORA3CYP3A4 | |
| SCHEMBL3069547 | 0.74 | ADORA2B (1.00) | ADORA2AADORA2BADORA1ADORA3CYP3A4 | |
| SCHEMBL3066805 | 0.74 | ADORA2B (1.00) | ADORA2AADORA2BADORA1ADORA3CYP3A4 | |
| SCHEMBL3063412 | 0.73 | ADORA2B (0.46) | ADORA2AADORA2BADORA1ADORA3CYP3A4 | |
| SCHEMBL3058619 | 0.72 | ADORA2B (0.61) | ADORA2AADORA2BADORA1ADORA3CYP3A4 | |
| SCHEMBL4053992 | 0.71 | ADORA2A (0.70) | ADORA2AADORA2BADORA1ADORA3CYP3A4 | |
| SCHEMBL14611374 | 0.71 | ADORA2B (0.64) | ADORA2AADORA2BADORA1ADORA3CYP3A4 | |
| SCHEMBL1256050 | 0.69 | ALDH1A1 (0.74) | ADORA2AADORA2BADORA1ADORA3CYP3A4 | |
| SCHEMBL3059123 | 0.69 | ADORA1 (0.60) | ADORA2AADORA2BADORA1ADORA3CYP3A4 | |
| SCHEMBL1255284 | 0.68 | L3MBTL1 (0.66) | ADORA2AADORA2BADORA1ADORA3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790728-B2 | Pyrazine derivatives useful as adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-07 | — | — | US | claimed |
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| US-20100273757-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. | 2010-10-28 | — | — | US | disclosed |
| US-20100273757-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. | 2010-10-28 | — | — | US | disclosed |
| US-20100273757-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. | 2010-10-28 | — | — | US | disclosed |
| US-7790728-B2 | Pyrazine derivatives useful as adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-07 | — | — | US | disclosed |
| US-7790728-B2 | Pyrazine derivatives useful as adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-07 | — | — | US | disclosed |
| US-7790728-B2 | Pyrazine derivatives useful as adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-07 | — | — | US | disclosed |
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| WO-2007017096-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA2B 1/4885ADORA1 4/4885 |
| US-20100273757-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA2B 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.